Saluda Medical’s Post

Last month, the 2025 Spanish SENSE Meeting in Madrid provided an excellent opportunity to share knowledge on the Evoke® system with SmartLoop® technology, and to highlight how our commitment to data allows us to precisely know and control the dose to deliver long-term pain relief. A big thank you to all the attendees and to our esteemed faculty for sharing their valuable insights. Together, we’re transforming lives. Dr David Abejon Dr M. Angeles Canos Dr Jose De Andres Dr Harold Nijhuis @ Dr Bjorn Carsten Schultheis #KnowTheDose #ControltheDose #ClosedLoop #Sensing #Education #SENSE To learn more about the Evoke® System, visit: https://lnkd.in/gX6abP8Z Risks and Important Safety Info https://lnkd.in/d2XZ_Asn Rx Only The Saluda Medical Evoke® SCS System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs.

  • graphical user interface, website
Kirsten Wyzanski

Marketing & Communications Executive I Commercialization Strategies I Data Driven Digital Strategy I MedTech I Orthopaedics & Disruptive Technologies

4d

Congratulations Saluda Medical ! Madrid experiencing the value of Evoke!

Like
Reply
Beth Best

Orthopedics; Sports Medicine; and Interventional Pain | Marketing Exec | Medical Device & Biopharm | Performance Fashion Commercialization (Marketing, PR, IR)| KOL Ad Boards | Post Acquisition Customer Integration.

4d

Congratulations to Saluda Medical for another successful #SenseSummit. #rigorousscience #objectivedata

Like
Reply
Jim Schuermann

CEO at Saluda Medical closed-loop neuromodulation

14h

Thank you David Abejon M. Angeles Canos Jose De Andres Harold Nijhuis and Bjorn Carsten Schultheis for advancing #Evoke closed-loop #SCS in #Spain

Tim Palmer

Head of European Sales at Saluda Medical

4d

A fantastic meeting with great content. Thank you to the faculty and all who attended

Like
Reply

A step forward in spinal cord stimulation therapy!

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics